The Food and Drug Administration on Friday approved a longdelayed inhalable diabetes medication to help patients control their blood sugar levels The FDA cleared MannKind Corps drug Afrezza a fastacting form of insulin for adults with the most common form of diabetes that affects more than  million Americans Diabetes is a chronic condition in which the body either does not make enough insulin to break down the sugar in foods or uses insulin inefficiently It can lead to blindness strokes heart disease or death In type  diabetes the most common form of the disease the body does not use insulin properly Type  diabetes is usually diagnosed in children and young adults In those cases the body does not produce insulin Afrezza an insulin powder comes in a singleuse cartridge and is designed to be inhaled at the start of a meal or within  minutes of starting The Associated Press